Top Markets
#1 CoW Protocol CoW Protocol +59.38%
#2 EXOD EXOD +56.80%
#3 Glidr Glidr +39.17%
#4 Cysic Cysic +35.83%
#5 Walrus Walrus +25.40%
#6 Humanity Humanity +22.30%
#7 Enso Enso +17.07%
#8 Velvet Velvet +17.00%
#9 Tutorial Tutorial +16.94%
#10 Codatta Codatta +14.78%
Coin of the day
CoW Protocol CoW Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Magenta Therapeutics, Inc. Magenta Therapeutics, Inc.

Magenta Therapeutics, Inc.

MGTA
Classifica tra le azioni #36943
Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development... Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials. Additionally, the company is developing a CD45-antibody drug conjugate, designed to target both HSCs and immune cells. This asset is in investigational new drug (IND) enabling studies, exploring its potential as a monotherapy for autoimmune diseases and in hematology-oncology transplant settings. Another therapeutic, MGTA-145, is undergoing Phase II clinical evaluation for its application in both autologous and allogeneic transplant procedures. Beyond these, Magenta boasts a cell therapy initiative featuring E478, a small molecule aryl hydrocarbon receptor antagonist, which is being explored for stem cell-based gene therapy and genome editing. The company actively engages in strategic alliances, including a research and clinical collaboration with AVROBIO, Inc. focused on treating lysosomal storage disorders. Furthermore, it partners with Beam Therapeutics, Inc. to investigate the utility of MGTA-117 as a conditioning regimen for patients with sickle cell disease and beta-thalassemia. Originally incorporated in 2015 as HSCTCo Therapeutics, Inc., the company adopted its current name, Magenta Therapeutics, Inc., in February 2016. Its corporate headquarters are situated in Cambridge, Massachusetts.
Prezzo delle azioni
$0.6996
Ultima sincronizzazione: 2023-09-11
Capitalizzazione di mercato
$2.19M
Variazione (1 giorno)
-7.74%
Variazione (1 anno)
0.00%
Paese
US
Scambia Magenta Therapeutics, Inc. (MGTA)

Categoria

Healthcare
EPS per Magenta Therapeutics, Inc. (MGTA)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Magenta Therapeutics, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per Magenta Therapeutics, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE